Pityriasis rosea
Exam Tips
- Most exam-stem clue: herald patch appears first, then a bilateral truncal eruption with collarette scale in a cleavage-line ("Christmas-tree") pattern.
- If palms/soles are involved, actively exclude secondary syphilis and HIV rather than assuming atypical pityriasis rosea.
- PR-like drug eruption is often itchier, lacks a herald patch, and may show eosinophilia.
- Dark skin may show hypopigmented lesions and higher rates of facial/scalp/oral involvement; inspect mucosa and scalp deliberately.
- Management is usually reassurance plus itch control; refer if diagnosis is uncertain, atypical, severe, or persistent beyond 3 months.
- For visual pattern recognition revision, review standard dermatology image atlases (for example DermNet pityriasis rosea image set).
Definition
Pityriasis rosea is an acute, usually self-limiting papulosquamous eruption seen most often in adolescents and young adults, classically beginning with a solitary herald patch followed days to weeks later by a more generalised rash. The secondary eruption is typically oval, salmon-pink lesions with peripheral collarette scale distributed along skin cleavage lines on the trunk, often creating a "Christmas-tree" pattern.
Pathophysiology
The exact mechanism is not fully established, but the leading model is viral reactivation (particularly HHV-6/HHV-7) after latent infection, triggering a transient inflammatory skin reaction. A first larger lesion (herald patch) is followed by a delayed immune-mediated exanthem with multiple smaller lesions, reflecting a wave-like cutaneous inflammatory response rather than ongoing contagious spread. Histologically, pityriasis rosea behaves like a self-limited interface/spongiotic dermatitis, which helps explain scaling, mild erythema, and spontaneous resolution.
Risk Factors
- Age 10-35 years (peak incidence)
- Female sex (slightly higher incidence than males)
- Winter months in temperate climates
- Possible recent viral prodrome (upper respiratory or systemic symptoms)
- Drug exposure causing PR-like eruptions (for example ACE inhibitors, beta-blockers, lamotrigine, terbinafine, NSAIDs, metronidazole, omeprazole, isotretinoin, interferon, clonidine, gold, and some vaccines)
Clinical Features
Symptoms
- Often asymptomatic or mildly itchy rash
- Pruritus that may disturb sleep
- Possible prodromal malaise, headache, sore throat, low-grade fever, nausea, or arthralgia
- Occasional oral discomfort if mucosal lesions are present
Signs
- Herald patch (usually 2-5 cm), oval, erythematous, with collarette scale and central wrinkling/depression
- Secondary eruption of multiple discrete oval pink-red (or hypopigmented in darker skin) lesions, typically 0.5-1 cm
- Peripheral collarette scaling with non-vesicular lesions
- Symmetrical truncal and proximal limb distribution; lesions align with cleavage lines ("Christmas-tree" pattern on back/chest)
- Usually spares palms and soles; facial/scalp involvement is more common in children and in darker skin
- Atypical variants can be inverse (axillae/groin/face), giant, purpuric, vesicular, papular, pustular, or urticarial
Investigations
Management
Lifestyle Modifications
- Reassure: condition is benign, self-limiting, and usually non-contagious
- Explain natural history: new crops may appear for up to 6 weeks before settling
- Use regular emollients and avoid irritant soaps/fragranced products
- Advise gentle skin care and avoidance of overheating/friction that may worsen itch
- Safety-net: seek review if rash lasts >3 months, becomes atypical, or systemic features develop
- In first-trimester pregnancy, discuss early with obstetric/dermatology teams if diagnosis is uncertain or disease is extensive
Pharmacological Treatment
Emollients
- White soft paraffin/liquid paraffin 50:50 ointment, apply liberally as needed
- Cream/ointment emollient of patient preference, frequent application
First-line for itch and barrier support; no maximum daily dose, but encourage frequent use.
Oral antihistamine (off-label for itch in pityriasis rosea)
- Chlorphenamine 4 mg orally at night (adult), may use 4 mg every 4-6 hours if needed; max 24 mg/day
Use mainly when nocturnal itch affects sleep; review at 2 weeks and stop if ineffective. Warn about sedation, impaired driving, and additive CNS depression with alcohol/opioids.
Topical corticosteroids for itch/inflammation
- Hydrocortisone 1% cream/ointment, thin layer once or twice daily for up to 4 weeks
- Betamethasone valerate 0.025% cream/ointment, thin layer once or twice daily for up to 4 weeks
- Clobetasone butyrate 0.05% cream/ointment, thin layer once or twice daily for up to 4 weeks
Choose potency by itch severity and site. Avoid prolonged continuous use on face/flexures/genitals; caution in infants and young children due to increased absorption.
Antiviral (specialist-directed, selected severe/early cases, especially pregnancy concerns)
- Aciclovir oral (off-label for pityriasis rosea): commonly 400-800 mg five times daily for 7 days in published regimens
Not routine primary-care treatment. Use only after specialist advice; check renal function and hydration, adjust dose in renal impairment, and review pregnancy risk-benefit.
Complications
- Post-inflammatory hyperpigmentation or hypopigmentation (more common in darker skin, can persist for months)
- Sleep disturbance and reduced quality of life from pruritus
- Rare recurrence (about 3-4%), usually milder and may lack herald patch
- Inconclusive signal of adverse pregnancy outcomes when onset is in first trimester (for example miscarriage or preterm delivery), requiring cautious multidisciplinary review
Prognosis
Excellent overall. Most cases resolve spontaneously within 2-12 weeks (mean about 45 days), though some persist up to around 5 months; new lesions can continue to appear during the first 6 weeks. Scarring is not expected, but temporary pigmentary change may remain after rash clearance.
Sources & References
🏥BMJ Best Practice(1)
✅NICE Guidelines(1)
- Pityriasis rosea[overview]
📖Textbook References(10)
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1840)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1643)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1599, 1600)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1600)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1643)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1652)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1651, 1652)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1643)[context]
- Oxford Handbook of Clinical Diagnosis (Huw Llewelyn, Hock Aun Ang, Keir Lewis etc.) (Z-Library).pdf(pp. 168)[context]
- Oxford Handbook of Clinical Diagnosis (Huw Llewelyn, Hock Aun Ang, Keir Lewis etc.) (Z-Library).pdf(pp. 167, 168)[context]